503 related articles for article (PubMed ID: 8669820)
1. Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats.
Esposito M; Vannozzi M; Viale M; Pellecchia C; Civalleri D; Gogioso L
Anticancer Res; 1995; 15(6B):2541-7. PubMed ID: 8669820
[TBL] [Abstract][Full Text] [Related]
2. Para-aminobenzoic acid suppression of cis-diamminedichloroplatinum(II) nephrotoxicity.
Esposito M; Vannozzi MO; Viale M; Fulco RA; Collecchi P; Merlo F; De Cian F; Zicca A; Cadoni A; Poirier MC
Carcinogenesis; 1993 Dec; 14(12):2595-9. PubMed ID: 8269632
[TBL] [Abstract][Full Text] [Related]
3. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
Deng C; Huang R; Lian L
Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions.
Kurihara N; Kubota T; Hoshiya Y; Otani Y; Ando N; Kumai K; Kitajima M
J Surg Oncol; 1996 Jun; 62(2):135-8. PubMed ID: 8649040
[TBL] [Abstract][Full Text] [Related]
6. Effect of normal saline on cisplatin pharmacokinetics and antitumor activity in mice bearing P388 leukemia.
Fulco RA; Vannozzi M; Collecchi P; Merlo F; Parodi B; Civalleri D; Esposito M
Anticancer Res; 1990; 10(6):1603-10. PubMed ID: 2285232
[TBL] [Abstract][Full Text] [Related]
7. Chemical and biological properties of a new cis-diammineplatinum (II) complex containing para-aminobenzoic acid as amino ligand.
Parodi B; Esposito M; Viale M; Cafaggi S; Vannozzi M
Anticancer Res; 1995; 15(3):895-9. PubMed ID: 7645978
[TBL] [Abstract][Full Text] [Related]
8. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
de Jong WH; Steerenberg PA; Vos JG; Bulten EJ; Verbeek F; Kruizinga W; Ruitenberg EJ
Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
[TBL] [Abstract][Full Text] [Related]
10. Effect of a forced diuresis on the distribution and excretion (via urine and bile) of 195mplatinum when given as 195mplatinum cis-dichlorodiammineplatinum(II).
DeSimone PA; Yancey RS; Coupal JJ; Butts JD; Hoeschel JD
Cancer Treat Rep; 1979 Jun; 63(6):951-60. PubMed ID: 466654
[TBL] [Abstract][Full Text] [Related]
11. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role?
Viale M; Vannozzi MO; Pastrone I; Mariggiò MA; Zicca A; Cadoni A; Cafaggi S; Tolino G; Lunardi G; Civalleri D; Lindup WE; Esposito M
J Pharmacol Exp Ther; 2000 Jun; 293(3):829-36. PubMed ID: 10869382
[TBL] [Abstract][Full Text] [Related]
12. Antitumour activity of cis-diamminedichloroplatinum (II) against human tumour xenografts depends on its area under the curve in nude mice.
Kurihara N; Kubota T; Hoshiya Y; Otani Y; Watanabe M; Kumai K; Kitajima M
J Surg Oncol; 1996 Feb; 61(2):138-42. PubMed ID: 8606546
[TBL] [Abstract][Full Text] [Related]
13. Quiescent LLC-PK1 cells as a model for cis-diamminedichloroplatinum(II) nephrotoxicity and modulation by thiol rescue agents.
Montine TJ; Borch RF
Cancer Res; 1988 Nov; 48(21):6017-24. PubMed ID: 2458831
[TBL] [Abstract][Full Text] [Related]
14. [Prophylactic effect of methylprednisolone on cisplatin-induced nephrotoxicity].
Koikawa Y
Fukuoka Igaku Zasshi; 1995 Feb; 86(2):31-9. PubMed ID: 7729781
[TBL] [Abstract][Full Text] [Related]
15. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
[TBL] [Abstract][Full Text] [Related]
16. Cis-diamminedichloroplatinum (II)-procaine pharmacokinetic interaction in mice bearing P388 leukemia.
Esposito M; Vannozzi MO; Viale M; Pellecchia C; Merlo F; Cadoni A; Cafaggi S; Parodi B; Lerza R; Poirier MC
Anticancer Res; 1993; 13(5A):1511-6. PubMed ID: 8239529
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
Egorin MJ; Van Echo DA; Tipping SJ; Olman EA; Whitacre MY; Thompson BW; Aisner J
Cancer Res; 1984 Nov; 44(11):5432-8. PubMed ID: 6386150
[TBL] [Abstract][Full Text] [Related]
18. cis-diamminedichloroplatinum(II) nephrotoxicity: tubular function after rescue with sodium diethyldithiocarbamate in rats.
Elliott WC; Newcom SR; Houghton DC; Baines-Hunter J; Bennett WM
Cancer Res; 1983 Aug; 43(8):3759-62. PubMed ID: 6305493
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and tissue distribution of novel traditional Chinese medicine-platinum anticancer agents in rats.
Wang X; Au-Yeung SC; Ho YP
J Inorg Biochem; 2007 Jun; 101(6):909-17. PubMed ID: 17428541
[TBL] [Abstract][Full Text] [Related]
20. Effect of selenium in combination with cis-diamminedichloroplatinum(II) in the treatment of murine fibrosarcoma.
Berry JP; Pauwells C; Tlouzeau S; Lespinats G
Cancer Res; 1984 Jul; 44(7):2864-8. PubMed ID: 6539165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
